MX2018014260A - Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma. - Google Patents

Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma.

Info

Publication number
MX2018014260A
MX2018014260A MX2018014260A MX2018014260A MX2018014260A MX 2018014260 A MX2018014260 A MX 2018014260A MX 2018014260 A MX2018014260 A MX 2018014260A MX 2018014260 A MX2018014260 A MX 2018014260A MX 2018014260 A MX2018014260 A MX 2018014260A
Authority
MX
Mexico
Prior art keywords
racecadotril
preparing
same
pharmaceutical composition
relates
Prior art date
Application number
MX2018014260A
Other languages
English (en)
Inventor
B Chaudhari Mahendra
Y Chaudhari Amol
P Nehete Nitin
Original Assignee
Athena Pharmaceutiques Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Pharmaceutiques Sas filed Critical Athena Pharmaceutiques Sas
Publication of MX2018014260A publication Critical patent/MX2018014260A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende racecadotrilo y azúcar cocristalizado y a un procedimiento para preparar la misma.
MX2018014260A 2017-03-06 2018-02-20 Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma. MX2018014260A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721007797 2017-03-06
PCT/IN2018/050085 WO2018163195A1 (en) 2017-03-06 2018-02-20 A pharmaceutical composition comprising racecadotril and process for preparing the same

Publications (1)

Publication Number Publication Date
MX2018014260A true MX2018014260A (es) 2019-04-29

Family

ID=63447638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014260A MX2018014260A (es) 2017-03-06 2018-02-20 Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma.

Country Status (10)

Country Link
US (1) US20200061014A1 (es)
EP (1) EP3592333B1 (es)
KR (1) KR102195776B1 (es)
CN (1) CN108834401A (es)
BR (1) BR112018069973A2 (es)
ES (1) ES2978020T3 (es)
MX (1) MX2018014260A (es)
PL (1) PL3592333T3 (es)
RU (1) RU2749949C2 (es)
WO (1) WO2018163195A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US6214402B1 (en) * 1998-09-17 2001-04-10 The Nutrasweet Company Co-crystallization of sugar and n-[n-(3,3-dimethylbutyl)-l αaspartyl]-l-phenylalanine 1-methyl ester
CN102151247A (zh) * 2000-06-23 2011-08-17 生物计划公司 包含外消旋卡朵曲的干粉制剂
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
KR20120048046A (ko) * 2004-02-06 2012-05-14 세파론, 인코포레이티드 모다피닐 조성물
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
WO2007144683A1 (es) * 2006-06-13 2007-12-21 Ingenio Del Cauca S.A. - Incauca S.A. Proceso de co-cristalización de sacarosa y un edulcorante natural y el producto obtenido
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
PT2866802T (pt) * 2012-06-28 2016-09-05 Johnson & Johnson Consumer Inc Composições líquidas racecadotril
TR201801726T4 (tr) * 2012-12-26 2018-03-21 Ilko Ilac Sanayi Veticaret A S Rasekadotri̇l ve farmasöti̇k bi̇leşi̇mleri̇.
CN104224724A (zh) * 2013-06-08 2014-12-24 北京韩美药品有限公司 一种消旋卡多曲颗粒剂及其制备工艺
CN103565750A (zh) * 2013-09-30 2014-02-12 北京德众万全药物技术开发有限公司 消旋卡多曲颗粒及其制备方法
ES2555484T1 (es) * 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
MA40859A (fr) * 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril

Also Published As

Publication number Publication date
ES2978020T3 (es) 2024-09-04
RU2018131133A3 (es) 2021-01-22
EP3592333A1 (en) 2020-01-15
PL3592333T3 (pl) 2024-06-17
KR20180129807A (ko) 2018-12-05
EP3592333C0 (en) 2024-04-03
RU2018131133A (ru) 2021-01-22
CN108834401A (zh) 2018-11-16
EP3592333B1 (en) 2024-04-03
WO2018163195A1 (en) 2018-09-13
US20200061014A1 (en) 2020-02-27
EP3592333A4 (en) 2020-08-19
BR112018069973A2 (pt) 2019-09-17
RU2749949C2 (ru) 2021-06-21
KR102195776B1 (ko) 2020-12-29

Similar Documents

Publication Publication Date Title
ZA201802657B (en) Crystal forms of beta-nicotinamide mononucleotide
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
EP3709944A4 (en) BUFFERED ADHESIVE COMPOSITIONS FOR SKIN ADHESIVE MEDICAL PRODUCTS
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
EP3359193A4 (en) Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
EP3600368A4 (en) MEDICINAL COMPOSITION DERIVED FROM MULTIPLE PLANT SOURCES FOR GASTROINTESTINAL DISORDER
MX2019008917A (es) Composiciones farmaceuticas para terapia de combinacion.
AU2018302170A1 (en) Pharmaceutical compositions comprising entrectinib
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
EP3572095A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HTLV-1 ASSOCIATED MYELOPATHIA
NZ728401A (en) High purity oritavancin and method of producing same
EP3581183A4 (en) PHARMACEUTICAL COMPOSITION FOR ONCOTHERAPY
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
PH12017502028A1 (en) Vortioxetine pyroglutamate
EP3275454A4 (en) Pharmaceutical composition containing silybin, ve and l-carnitine
EP3583943A4 (en) PHARMACEUTICAL COMPOSITION
EP3868371A4 (en) NOVEL PHARMACEUTICAL COMPOSITION
IN2014CH00840A (es)
EP3590515A4 (en) DRUG PRODUCT
IN2014MU00916A (es)
EP3720844A4 (en) MEDICINAL COMPOSITIONS
EP3646867A4 (en) PHARMACEUTICAL COMPOSITION
EP3646863A4 (en) PHARMACEUTICAL COMPOSITION
EP3616722A4 (en) PHARMACEUTICAL COMPOSITION